Vir Biotechnology Inc (VIR)

NASDAQ
Currency in USD
5.23
+0.02(+0.38%)
Closed·
After Hours
5.31+0.11(+2.12%)
·
VIR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
5.105.31
52 wk Range
4.3214.45
Key Statistics
Edit
Prev. Close
5.21
Open
5.25
Day's Range
5.1-5.31
52 wk Range
4.32-14.45
Volume
2.95M
Average Volume (3m)
1.34M
1-Year Change
-42.78%
Book Value / Share
7.61
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VIR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.88
Upside
+241.78%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings upwards for the upcoming period

Vir Biotechnology Inc News & Analysis

Show more

Vir Biotech Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Vir Biotechnology Inc SWOT Analysis


Hepatitis Breakthrough
Vir Biotechnology's promising Phase 2 results in chronic hepatitis delta and B treatments position it as a potential market leader in addressing unmet medical needs
Financial Crossroads
Despite a strong cash position, Vir faces challenges with negative EBITDA and EPS estimates, balancing R&D investments against the path to profitability
Pipeline Potential
Explore Vir's diverse portfolio, including viral hepatitis programs and T-cell engagers, with peak revenue estimates exceeding $10 billion annually
Market Valuation
Analyst price targets range from $10 to $110 per share, reflecting varied perspectives on Vir's growth potential amid clinical advancements and market opportunities
Read full SWOT analysis

Vir Biotechnology Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS at -$0.88, slightly missing forecast; revenue at $3.03M, significantly below $13.65M projection
  • R&D expenses increased to $118.6M from $100.1M YoY; net loss widened to $121M from $65.3M in Q1 2024
  • Stock declined 2.67% after-hours to $5.46; analysts set price targets from $14 to $110
  • Company focuses on ECLIPSE Phase 3 trials for Hepatitis Delta and advancing oncology programs
  • CEO emphasizes operational excellence; CMO highlights potential of dual-masked T cell engager technology
Last Updated: 08-05-2025, 03:06 am
Read Full Transcript

Compare VIR to Peers and Sector

Metrics to compare
VIR
Peers
Sector
Relationship
P/E Ratio
−1.3x−9.3x−0.5x
PEG Ratio
0.24−0.060.00
Price/Book
0.7x1.3x2.6x
Price / LTM Sales
34.7x4.0x3.0x
Upside (Analyst Target)
196.4%238.5%52.4%
Fair Value Upside
Unlock43.0%8.7%Unlock

Analyst Ratings

7 Buy
2 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 17.88
(+241.78% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.88 / -0.87
Revenue / Forecast
3.03M / 13.65M
EPS Revisions
Last 90 days

VIR Income Statement

FAQ

What Is the Vir Biotech (VIR) Stock Price Today?

The Vir Biotech stock price today is 5.23.

What Stock Exchange Does Vir Biotech Trade On?

Vir Biotech is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Vir Biotech?

The stock symbol for Vir Biotech is "VIR."

What Is the Vir Biotech Market Cap?

As of today, Vir Biotech market cap is 722.98M.

What Is Vir Biotech's Earnings Per Share (TTM)?

The Vir Biotech EPS (TTM) is -4.22.

When Is the Next Vir Biotech Earnings Date?

Vir Biotech will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is VIR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Vir Biotech Stock Split?

Vir Biotech has split 0 times.

How Many Employees Does Vir Biotech Have?

Vir Biotech has 408 employees.

What is the current trading status of Vir Biotech (VIR)?

As of 22 Jun 2025, Vir Biotech (VIR) is trading at a price of 5.23, with a previous close of 5.21. The stock has fluctuated within a day range of 5.10 to 5.31, while its 52-week range spans from 4.32 to 14.45.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.